Patents by Inventor Dieter Hamprecht

Dieter Hamprecht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11180461
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 23, 2021
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Publication number: 20200377485
    Abstract: The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    Type: Application
    Filed: December 16, 2016
    Publication date: December 3, 2020
    Inventors: Giuseppe ALVARO, Agostino MARASCO, Dieter HAMPRECHT, Anne DECOR
  • Publication number: 20200172496
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 4, 2020
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Publication number: 20200163964
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Inventors: Giuseppe ALVARO, Anne DECOR, Stefano FONTANA, Dieter HAMPRECHT, Charles LARGE, Agostino MARASCO
  • Patent number: 10640486
    Abstract: The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: May 5, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Remko Bakker, Riccardo Giovannini, Giacomo Fossati, Dieter Hamprecht, Iain Lingard, Alexander Pautsch, Bernd Wellenzohn
  • Patent number: 10632118
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: April 28, 2020
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Giuseppe Alvaro, Anne Decor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • Patent number: 10611735
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: April 7, 2020
    Assignee: Autifony Therapeutics Limited
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Patent number: 10399961
    Abstract: The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: September 3, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sara Frattini, Remko Bakker, Riccardo Giovannini, Dieter Hamprecht, Iain Lingard, Alexander Pautsch, Bernd Wellenzohn
  • Publication number: 20190071405
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Patent number: 10221202
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, and Z? have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a medicament, to pharmaceutical compositions comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 5, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Dieter Hamprecht, Joerg Kley, Dieter Wiedenmayer
  • Patent number: 10160730
    Abstract: Compounds of formula (I) are of use in the modulation of Kv3.1, Kv.3.2 and Kv3.3 channels and have utility in the treatment or prevention of related disorders.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: December 25, 2018
    Assignee: Autifony Therapeutics Limited
    Inventors: Agostino Marasco, Giuseppe Alvaro, Anne Dècor, Dieter Hamprecht, Paolo Dambruoso, Simona Tommasi
  • Patent number: 10155749
    Abstract: The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z? have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Dieter Hamprecht, Joerg Kley
  • Publication number: 20180338974
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Application
    Filed: July 30, 2018
    Publication date: November 29, 2018
    Inventors: Giuseppe ALVARO, Anne Decor, Stefano fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • Publication number: 20180319771
    Abstract: The present invention relates to compounds of general formula (I), wherein D1 to D3, -A-, n, R1, R2, Y1, L and y2 are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Application
    Filed: October 20, 2016
    Publication date: November 8, 2018
    Inventors: Sara FRATTINI, Remko BAKKER, Riccardo GIOVANNINI, Giacomo FOSSATI, Dieter HAMPRECHT, Iain LINGARD, Alexander PAUTSCH, Bernd WELLENZOHN
  • Publication number: 20180305338
    Abstract: The present invention relates to compounds of general formula I, wherein D1 to D3, A, R1, R2, Y and n are defined as in claim 1, which have valuable pharmacological properties, in particular are inhibitors of plasma kallikrein. The compounds are suitable for treatment and prevention of diseases which can be influenced by influenced by inhibition of plasma kallikrein, such as diabetic complications, particularly in the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema.
    Type: Application
    Filed: October 20, 2016
    Publication date: October 25, 2018
    Inventors: Sara FRATTINI, Remko BAKKER, Riccardo GIOVANNINI, Dieter HAMPRECHT, Iain LINGARD, Alexander PAUTSCH, Bernd WELLENZOHN
  • Patent number: 10058551
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 28, 2018
    Assignee: Autifony Therapeutics Limited
    Inventors: Giuseppe Alvaro, Anne Decor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • Publication number: 20180194747
    Abstract: The present invention relates to compounds of general formula (I) and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 12, 2018
    Inventors: Armin Heckel, Sara Frattini, Dieter Hamprecht, Joerg Kley
  • Publication number: 20180186774
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and Z? have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Application
    Filed: February 28, 2018
    Publication date: July 5, 2018
    Inventors: Armin HECKEL, Dieter HAMPRECHT, Joerg KLEY
  • Publication number: 20180105512
    Abstract: The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z? have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Application
    Filed: January 7, 2016
    Publication date: April 19, 2018
    Inventors: Armin HECKEL, Dieter HAMPRECHT, Joerg KLEY
  • Patent number: 9938256
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and Z? have one of the meanings as indicated in the specification or a pharmaceutically acceptable salt thereof, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: April 10, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Dieter Hamprecht, Joerg Kley